TSXV:BTI.H - Post by User
Comment by
prophetoffactzon Dec 23, 2022 7:45am
102 Views
Post# 35188993
RE:RE:Crisis in biotech - Biodexa addresses needs of the time
RE:RE:Crisis in biotech - Biodexa addresses needs of the timeBTI merges with similarly undervaluaed Midatech for ~15% of Biodexa's shares.
Biodexa secures access to potentially US$20 million cash through upfront cash and warrant exercise as 25% of biotech has recently been trading below cash during the worst biotech market in history.
Midatech's lead asset with $5 billion in potential nearer term revenue ramp can support an expansive pipeline of xB3 and Q-Sphera assets as the platforms advance into the clinic in the coming years potentially greatly limiting dilution. The market demands cashflow not concept stocks now.
Biodexa has increased scale to manage costs, infrastructure to support better deals, a better capital market profile to attact investors, and will be more credible accelerating dealflow.